Pfizer Inc. (NYSE:PFE) Shares Sold by Schulhoff & Co. Inc.

Schulhoff & Co. Inc. lessened its holdings in shares of Pfizer Inc. (NYSE:PFE) by 13.3% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 51,336 shares of the biopharmaceutical company’s stock after selling 7,852 shares during the quarter. Schulhoff & Co. Inc.’s holdings in Pfizer were worth $1,486,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of PFE. Brooktree Capital Management lifted its stake in Pfizer by 1.2% in the 3rd quarter. Brooktree Capital Management now owns 113,994 shares of the biopharmaceutical company’s stock worth $3,299,000 after purchasing an additional 1,316 shares in the last quarter. Curi RMB Capital LLC increased its holdings in shares of Pfizer by 4.7% in the third quarter. Curi RMB Capital LLC now owns 55,770 shares of the biopharmaceutical company’s stock valued at $1,614,000 after purchasing an additional 2,487 shares during the last quarter. KBC Group NV lifted its position in Pfizer by 26.0% during the third quarter. KBC Group NV now owns 3,105,433 shares of the biopharmaceutical company’s stock worth $89,872,000 after buying an additional 639,985 shares in the last quarter. Summit Asset Management LLC boosted its stake in Pfizer by 5.0% during the third quarter. Summit Asset Management LLC now owns 22,428 shares of the biopharmaceutical company’s stock worth $649,000 after buying an additional 1,063 shares during the last quarter. Finally, Plato Investment Management Ltd grew its holdings in Pfizer by 11.5% in the 3rd quarter. Plato Investment Management Ltd now owns 158,445 shares of the biopharmaceutical company’s stock valued at $4,581,000 after buying an additional 16,327 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the company. StockNews.com upgraded Pfizer from a “buy” rating to a “strong-buy” rating in a report on Tuesday. Evercore ISI raised shares of Pfizer to a “strong-buy” rating in a research note on Wednesday, October 30th. Daiwa Capital Markets raised shares of Pfizer from a “neutral” rating to an “outperform” rating and increased their price target for the company from $28.00 to $34.00 in a research note on Wednesday, August 7th. Citigroup started coverage on shares of Pfizer in a report on Friday, October 25th. They set a “neutral” rating and a $30.00 price target for the company. Finally, Wells Fargo & Company upped their price objective on Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a report on Wednesday, July 31st. Eight investment analysts have rated the stock with a hold rating, five have issued a buy rating and three have given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $33.58.

Pfizer Stock Down 0.1 %

Shares of NYSE:PFE opened at $26.70 on Thursday. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The stock has a market cap of $151.31 billion, a P/E ratio of 36.11, a P/E/G ratio of 0.83 and a beta of 0.67. Pfizer Inc. has a 1-year low of $25.20 and a 1-year high of $31.54. The firm has a fifty day moving average price of $28.76 and a 200 day moving average price of $28.67.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, topping analysts’ consensus estimates of $0.64 by $0.42. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The company had revenue of $17.70 billion during the quarter, compared to analysts’ expectations of $14.92 billion. During the same period last year, the firm earned ($0.17) EPS. The firm’s revenue for the quarter was up 31.2% on a year-over-year basis. Sell-side analysts predict that Pfizer Inc. will post 2.96 EPS for the current year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Friday, November 8th will be issued a dividend of $0.42 per share. The ex-dividend date is Friday, November 8th. This represents a $1.68 annualized dividend and a yield of 6.29%. Pfizer’s dividend payout ratio is currently 227.03%.

Insider Buying and Selling at Pfizer

In other Pfizer news, Director Scott Gottlieb acquired 1,000 shares of the business’s stock in a transaction on Wednesday, October 30th. The stock was purchased at an average price of $28.24 per share, for a total transaction of $28,240.00. Following the completion of the transaction, the director now owns 10,000 shares of the company’s stock, valued at $282,400. The trade was a 0.00 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.06% of the stock is owned by corporate insiders.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.